- Hemptown USA has built a business on cultivating cannabidiol (CBD), but now its focus has turned to the qualities of a little-marketed cannabinoid – cannabigerol (CBG)
- CBG is known as the “Mother of all Cannabinoids” because its acid form is the precursor to the three main cannabinoids and is synthesized to create those extracts very early in the plants’ maturation process
- Hemptown has 500 acres dedicated exclusively to CBG cultivation in Oregon, using the company’s rights to one million cannabigerol (CBG)-intensive seeds that are engineered to preserve CBG in its latent form until late in the plant’s growth cycle
While cannabis enthusiasts, commercial enterprises and investors are all too familiar with the uses and usefulness of plant extracts cannabidiol (CBD) and tetrahydrocannabinol (THC), Southern Oregon-based Hemptown USA is touting the virtues of another cannabinoid – non-psychoactive cannabigerol (CBG) – and the company’s recent harvest will strategically position them to be the largest producer of it in North America.
Hemptown USA operates a farm operation with more than 500 acres dedicated to the exclusive cultivation of CBG, utilizing one million rare cannabigerol (CBG)-intensive seeds acquired earlier this year.
The seeds are genetically programmed to yield up to 14 percent CBG by allowing the plants to reach full maturity before being harvested, whereas normally plants would have to be harvested early in their growth cycles in order to obtain CBG before its acid form is synthesized as the acid form of one of the two main cannabinoids – CBD and THC.
Hemptown USA has built CBD production from broad-spectrum hemp biomass in states such as Oregon, Kentucky and Colorado, but has worked to increase its profile as hemp-friendly laws have been enacted – particularly last year’s Farm Bill that legalized commercial hemp cultivation nationwide following years of prohibition.
The company’s focus on its CBG-growing resources is part of an ongoing effort to serve an increasingly health-conscious society’s desire for wellness based on natural elements with minimal pharmaceutical involvement.
During the decades of prohibition when it was generally illegal to grow or consume cannabis, research into the suspected medicinal properties of compounds such as CBG was virtually non-existent at any scientific level. CBG’s rarity further minimized the potential for such investigation so there still exists a degree of uncertainty about what CBG can accomplish. However, recent studies have shown some indications that CBG may help with psoriasis, eczema, colitis, neurodegeneration, and cancer, with suspected additional benefits in combatting glaucoma, bacterial infections, muscular tension and symptoms of inflammation (http://ibn.fm/RBcJo).
Hemptown USA believes its Oregon acreage and seed stock will grant it control of 40 percent of the North American supply of CBG.
“The passage of the 2018 Farm Bill opened doors for commercial cultivation of CBD-rich hemp, as well as hemp rich in other, so-called, ‘novel’ cannabinoids. We believe that all cannabinoids will eventually be commoditized. We strive to be leaders in the space, bringing new cannabinoids to the market over the next couple years,” Hemptown Chairman Rod Wolterman stated in a report for cannabis media outlet Leafly last month (http://ibn.fm/Z4xLM).
The company was first to market a CBD and CBG-infused chewing gum when it launched its Hemptown Chew in September. The gum contains 15 mg of CBD and 5 mg of CBG, sold in packs of two, six and 12 servings (http://ibn.fm/bGAtX).
For more information, visit the company’s website at www.HemptownUSA.com
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.